Who is sponsoring NCT06723561?

NCT06723561 is sponsored by Medical College of Wisconsin.

What drugs are being tested in NCT06723561?

Interventions in NCT06723561: 4.5mg daily dose of naltrexone.

What condition does NCT06723561 study?

NCT06723561 studies Central Neuropathic Pain, Spinal Cord Injury.

Is NCT06723561 still recruiting?

NCT06723561 is currently recruiting now. Last updated 21 October 2025.

Last reviewed 2025-10-21 · How we verify

NCT06723561

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Treating Central Neuropathic Pain With Low Dose Naltrexone for People With Spinal Cord Injury

Recruiting now Phase 2 Last updated 21 October 2025

What this trial tests

Phase 2 trial testing 4.5mg daily dose of naltrexone in Central Neuropathic Pain in 10 participants. Currently enrolling.

Timeline

1 February 2025

Primary endpoint
30 June 2026

31 December 2026

Quick facts

Lead sponsor	Medical College of Wisconsin
Phase	Phase 2
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	10
Start date	1 February 2025
Primary completion	30 June 2026
Estimated completion	31 December 2026
Sites	1 location across United States

Drugs / interventions tested

4.5mg daily dose of naltrexone — full drug profile →

Conditions studied

Central Neuropathic Pain — all drugs for Central Neuropathic Pain →
Spinal Cord Injury — all drugs for Spinal Cord Injury →

Sponsor

Medical College of Wisconsin

Who can join

18 and older, any sex, with Central Neuropathic Pain or Spinal Cord Injury. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The goal of this pilot clinical trial is to find out how well low dose naltrexone works for people with pain due to spinal cord injury. The main questions it aims to answer are: will low dose naltrexone reduce pain, and increase the quality of life for people with central neuropathic pain due to spinal cord injury. Hypothesis 1: LDN will decrease the severity of CNP in adult patients with SCI as measured by the Neuropathic Pain Scale (NPS) Hypothesis 2: LDN will improve quality of life of patients with SCI as measured by various validated clinical tools There is no comparison group. This study is being completed to give investigators more information for how to best run a larger clinical trial. Participants will be asked to take an oral dose of 4.5mg of naltrexone, daily, for 12 weeks.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Central Neuropathic Pain

Currently open trials in the same condition.

NCT06978764 — Low Intensity Focused Ultrasound Modulation of Thalamic Nuclei for Central Neuropathic Pain. · Phase 1 · active not recruiting
NCT06531317 — Machine-Learning Based EEG Biomarkers for Personalized Interventions · recruiting
NCT05357066 — Nitrous Oxide as Treatment for Fibromyalgia · Phase 2 · recruiting

Other Medical College of Wisconsin trials

Trials by the same sponsor.

NCT07260552 — Rapid Engagement for Solutions to Population and Outcomes Through Networked Dialogue for Coronary Heart Disease · not yet recruiting
NCT06795360 — Weight Changes After Incretin-mimetics · NA · not yet recruiting
NCT07228208 — Role of Endothelial Dysfunction on Exercise Pressor Reflex in Type 2 Diabetes · NA · not yet recruiting
NCT07298460 — Stimulation-based Therapy to Improve Balance in DCM · Phase 1, PHASE2 · not yet recruiting
NCT07434544 — Cardiometabolic Effects of Non-Nutritive Sweeteners (NNS) in Type 1 Diabetes (T1D) · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06723561 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Medical College of Wisconsin
Last refreshed: 21 October 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06723561.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing